Reneo Pharmaceuticals, Inc. (RPHM)

NASDAQ: RPHM · IEX Real-Time Price · USD
+0.15 (2.63%)
At close: Mar 20, 2023, 4:00 PM
-0.29 (-4.95%)
After-hours: Mar 20, 2023, 7:21 PM EDT

Company Description

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases.

It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V.

Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Reneo Pharmaceuticals, Inc.
Reneo Pharmaceuticals logo
Country United States
Founded 2014
IPO Date Apr 9, 2021
Industry Biotechnology
Sector Healthcare
Employees 32
CEO Mr. Gregory J. Flesher

Contact Details

18575 Jamboree Road, Suite 275-s
Irvine, California 92612
United States
Phone (858) 283-0280

Stock Details

Ticker Symbol RPHM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $15.00
CIK Code 0001637715
CUSIP Number 75974E103
ISIN Number US75974E1038
Employer ID 47-2309515
SIC Code 2834

Key Executives

Name Position
Michael G. Grey Founder and Executive Chairman
Gregory J. Flesher President, Chief Executive Officer and Director
Michael P. Cruse Chief Operating Officer
Vineet R. Jindal Consultant
Jennifer P. Lam Principal Financial and Accounting Officer
Wendy S. Johnson M.B.A. Consultant
Dr. Alejandro Dorenbaum M.D. Chief Medical Officer
Lynn Purkins Ph.D. Senior Vice President of Clinical Operations
Ashley F. Hall J.D. Chief Development Officer

Latest SEC Filings

Date Type Title
Mar 14, 2023 8-K Current Report
Mar 10, 2023 8-K Current Report
Jan 9, 2023 8-K Current Report
Nov 8, 2022 10-Q Quarterly Report
Nov 8, 2022 8-K Current Report
Sep 30, 2022 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Aug 11, 2022 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Aug 9, 2022 10-Q Quarterly Report
Aug 9, 2022 8-K Current Report
Aug 2, 2022 8-K Current Report